Turning Point Brands (TPB) Signals Growth Drive Amid Tariff Tailwinds and an EPS Dip in Q2 2026
Turning Point Brands, Inc. (TPB) rolled out its second-quarter results for 2026 from Louisville, Kentucky, outlining a revenue story supported by Modern Oral momentum, a tariff refund tailwind to gross profit, and a cautious blink toward higher guidance for the full year. The numbers arrive with a familiar tension: top-line growth and an expanding product set on one side, and a meaningful EPS delta and lower profitability on the other. In investor-speak, you’ll want to compare the reported EPS to the EPS consensus and watch how the revenue forecast lines up with the company’s reiterated targets.
Revenue growth and segment highlights
Net sales climbed 22.6% year over year to $142.9 million, a commendable leap that TPB attributes to ongoing Modern Oral strength and an associated tariff refund that helped lift gross profit. The Modern Oral category is singled out as the growth engine, while legacy segments show a mixed bag—Stoker’s Net Sales up a solid 54.5%, contrasted with Zig-Zag down around 24.8% in the quarter. The company also flagged a tariff-related adjustment that put gross profit at $93.7 million, with a note that excluding the out-of-period COGS related to the tariff refund would yield $81.5 million in gross profit.
Profitability and cash-style metrics
Net income declined 75.2% to $3.6 million, underscoring the drag from higher operating investments and the one-time tariff effects embedded in the quarter’s results. Adjusted EBITDA decreased 50.0% to $15.2 million, which the company frames as inclusive of strategic investments in marketing, sales capabilities, and distribution initiatives. In line with standard disclosure practice, TPB notes that Schedule A provides a reconciliation to Net Income, and Schedule B covers a reconciliation to Diluted EPS.
EPS prints and what investors will watch next
Diluted EPS came in at $0.18, while Adjusted Diluted EPS stood at $0.23. Those figures compare with the prior-year period’s $0.79 and $0.98, respectively. It’s a stark year-over-year delta that won’t be cured by one-off tariff tweaks alone; the performance points to a shift in mix and higher brand-building spend. For readers focused on EPS and EPS consensus, the question is whether current guidance and the Modern Oral trajectory will lift the next few quarters toward a more favorable comparison. A potential earnings surprise becomes plausible if the Street’s revenue forecast and margin assumptions recast the investment phase as durable value rather than a temporary drag.
Guidance: raising the FY 2026 trajectory
Management raised the FY 2026 Modern Oral gross and net sales guidance, signaling confidence in the channel’s distribution gains and consumer demand. The company reiterates its strategic emphasis on growing its Modern Oral brand and expanding retail access, while noting that the current quarter’s profitability reflects deliberate investments that should translate into stronger revenue capture over the balance of the year. In the context of a competitive landscape for nicotine alternatives and modern oral products, TPB’s forward path appears anchored to expanding market share in the space—an outcome that would, in turn, influence the revenue forecast and the EPS trajectory over the medium term.
Operational context: tariff refunds, investments, and the longer arc
Tariffs and refunds are not just accounting footnotes here; they’re a reminder that the macro backdrop—trade policy, tariff exposure, and the speed of pass-through—can shape quarterly results in material but sometimes reversible ways. TPB’s gross profit uplift, aided by the tariff refund, highlights how one-time items can mask ongoing operating leverage. The prospect of continued investment in distribution and brand-building suggests a deliberate tilt toward top-line growth, which, if sustained, could eventually yield improved margins as fixed costs spread over higher volumes.
What this portends for TPB and peers in the sector
TPB’s quarter is a study in the power and fragility of growth via Modern Oral, an area of the tobacco and alternative nicotine market that’s drawing capital, attention, and regulatory scrutiny alike. If the revenue trajectory holds and the tariff-driven gross profit normalization persists, the company could see a more favorable revenue forecast and a reversion in profitability that aligns with its investment cadence. For sector peers, the message is twofold: (1) growth narratives centered on modern alternatives can deliver top-line upside even when GAAP earnings wobble; (2) one-time tariff and COGS adjustments deserve close scrutiny when evaluating true operating performance versus attribution to externalities. In practice, investors will watch how the up-print in Modern Oral sales translates into sustained gross margin and whether the EPS gap closes as the year progresses.
Bottom line: a growth plan wearing a driver’s cap
TPB’s Q2 2026 results underscore a balancing act common to growth-stage, brand-building companies: invest aggressively in market access and product platforms while monitoring the pace of earnings normalization. The EPS decline is a reminder that the company’s near-term path depends less on raw top-line velocity than on the durability of gross profit gains, the pace of operating-expense containment, and the timing of any tariff-driven reversals. If the Modern Oral push sustains revenue momentum and the guidance proves resilient, TPB could convert early-year growth into a more robust earnings trajectory, narrowing the gap to the EPS consensus by year-end. In risk terms, the main question remains whether the tariff tailwinds fade or whether the company’s investments fructify into a durable competitive advantage that makes the next quarter’s earnings surprise more about mix and scale than a single quarter’s tariff tilt.